Video
Dr. Chughtai discusses new pilot study on Rezum treatment for BPH
Author(s):
“We found that the adverse event rates have dropped dramatically, to about a third of what it was reported in the pivotal trial, but at the same time still had the same net benefits in terms of efficacy when it comes to Q max, symptomatic improvement, as well as PVR," said Bilal Chughtai, MD.
Video Player is loading.
In this video, Bilal Chughtai, MD, an associate professor of Urology at Weill Cornell Medical College, discusses the background and findings of his recent paper, "Pilot study of ‘less is more’ Rezum for treatment of BPH."
Related Videos
BPH: Strategies for Guiding Patients From Medication to Intervention
Impact of Robotic Procedures and Apps on Clinic Efficiency
Amy Krambeck, MD, on innovation and building strong programs in endourology
BPH Treatment and Impact on Sexual Health
Clinical Benefits of BPH Treatments
BPH Management: Patient Outcome Evolution
Resective Surgery and Minimally Invasive Procedures For BPH
Naeem Bhojani, MD, expands on key findings from WATER III trial
Naeem Bhojani, MD, discusses WATER III data on Aquablation vs enucleation for BPH
BPH: The Patient Journey
Related Content
